Effect of Cimetidine on Prolactin Secretion in Normal Controls and Hyperthyroid Patients
スポンサーリンク
概要
- 論文の詳細を見る
Nine healthy female controls and 10 hyperthyroid female patients were studied. The intravenous administration of 200 mg cimetidine, an H<SUB>2</SUB>-receptor antagonist, was followed by a significant and marked rise in serum prolactin levels in all control subjects. There was no significant difference in serum PRL response to cimetidine injection between the euthyroid controls and hyperthyroid patients. But max ΔPRL, the change from basal to peak values, is significantly lower in the hyperthyroid patients than in the controls. There was a significant negative correlation between max ΔPRL and serum T<SUB>4</SUB> or T<SUB>3</SUB> levels in hyperthyroid patients before and after treatment with MMI or PTU. It appears from our data that cimetidine induced PRL release was blunted in hyperthyroid patients.
- 社団法人 日本内分泌学会の論文
著者
-
YABANA Tsuyoshi
First Department of Internal Medicine, Sapporo Medical University School of Medicine
-
Yachi Akira
First Department Of Internal Medicine Sapporo Medical University
-
KAMIJO KEIICHI
First Department of Internal Medicine, Sapporo Medical College
-
KATO TERUO
First Department of Internal Medicine, Sapporo Medical College
-
SAITO AKIMITSU
First Department of Internal Medicine, Sapporo Medical College
-
KAWASAKI KIMIO
First Department of Internal Medicine, Sapporo Medical College
-
SUZUKI MITSUAKI
First Department of Internal Medicine, Sapporo Medical College
-
WADA TAKEO
Sapporo Medical College
-
YABANA TSUYOSHI
First Department of Internal Medicine, Sapporo Medical College
-
YACHI AKIRA
First Department of Internal Medicine, Sapporo Medical College
関連論文
- Gastric antral vascular ectasia causing severe anemia
- A Case with Isolated ACTH Deficiency Accompanying Chronic Thyroiditis
- Effect of Cimetidine on Prolactin Secretion in Normal Controls and Hyperthyroid Patients
- Evidence of Sex difference in Dopaminergic Modulation of Serum TSH Secretion in Primary Hypothyroidism
- Growth Hormone Response to Thyrotropin-Releasing Hormone in Cancer Patients